Ovarian Cancer

Left Ovary Carcinoma

Female, 71 years

Patient Internal ID: 183649376

ICD-10 code

C56 Malignant Neoplasm of Ovary

Diagnosis (Incl. Metastases/Stage) and Year

March 2011
Adenocarcinoma of Left Ovary, pT1cN0M0 Stage I. Disease progression in November 2018, Metastasis in Pelvic Area. Disease progression in April 2021, pT1cN2M1 G3 Stage 4, PR+, ER+ Metastasis in Spleen, Pelvic Lymph Nodes. Disease progression in July 2022, Metastasis in the Lungs, Pelvis area.

Previous Treatment

Surgery, Chemotherapy (Carboplatin), Surgery, Chemotherapy (Paclitaxel and Carboplatin) + Biological therapy (Bevacizumab), Chemotherapy (Carboplatin and Gemcitabine), Chemotherapy (Carboplatin).

Prognosis and Survival Expectation

The Metastatic Ovarian Cancer prognosis remains poor, with a median survival of ~32 months from diagnosis. The average relative 5-year survival rate for Distant Spread Ovarian Cancer is about 31%.

Treatment Provided

Autologous DCV (9 doses) over a period of 11 months.

Patient Survival/Condition and Year
Date of Review: 17/02/2024

The patient has survived for 11,5 years since diagnosis and 49 months since the disease progression. It can be concluded that the addition of  Immunotherapy, alongside Chemotherapy and Surgery, has extended patient survival by an estimate of around 17 months.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.

Ok